Catalyst4 reports $13.84 million MapLight Therapeutics common share purchase
MPLT•Catalyst4 reports open-market purchases of MapLight Therapeutics shares
Catalyst4, a 10% owner of Maplight Therapeutics, reported open-market purchases totaling 1,209,225 voting common shares.
Purchases were priced between $10.74 and $13.00 per share, based on reported trade prices and weighted averages.
Beneficial ownership rose to 20,906,689 voting common shares, held indirectly.
